- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03193931
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers (ELDORANDO)
February 3, 2023 updated by: AIO-Studien-gGmbH
A Randomized Phase II Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
The study is designed as an open-label, randomized, prospective, multicenter, phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with squamous carcinoma of the head and neck (HNSCC)
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hannover, Germany, 30625
- Medizinsche Hochschule Hannover
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cooperation and willingness to complete all aspects of the study
- Signed written informed consent must be given prior to study inclusion
- Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) not amenable to local therapies
- Progressive disease at study entry
- At least 1 measurable lesion according to RECIST 1.1
- No previous systemic treatment for metastatic disease
Not eligible for cisplatin-based chemotherapy, defined as:
- ECOG 2 [Eastern Cooperative Oncology Group] and/or
- Calculated CrCl [Creatinine Clearance] <60 mL/min (measured by MDRD)
- Age ≥ 18 years
- ECOG performance status 0 - 2
- Brain metastases require completion of local therapy with discontinuation of steroids prior to start of treatment
- If of childbearing potential, willingness to use highly effective contraceptive method for the duration of the study and 120 days after last dose, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally.
Adequate bone marrow function, liver and renal function:
- Absolute neutrophil count ≥ 1.5 x 109/L
- Thrombocytes ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL
- INR [international normalized ratio] ≤ 1.5 and PPT [partial prothrombin time] ≤ 1.5 x lower limit during the last 7 days before therapy
- Bilirubin < 1.5 x lower limit and
- AST (GOT) [aspartate aminotransferase] and ALT (GPT) [alanine transaminase] < 3 x lower limit (5 x lower limit in case of liver metastases)
- Tumor block or 20 slides must be available at study inclusion for central pathology testing
Exclusion Criteria:
- Live expectancy less than 3 months
- Nasopharynx carcinoma
- Anticancer treatment during the last 30 days prior to start of treatment, including systemic therapy, radiotherapy or major surgery
- Participation in a clinical trial within the last 30 days prior to study treatment
- History of allogeneic tissue/solid organ transplant
- History of pneumonitis that has required oral or i.v. steroids
- Evidence of interstitial lung disease
- Minor surgery ≤ 24 hours prior first dose of study treatment
- Symptomatic acute cardiovascular or cerebrovascular disease
- Known active HBV [hepatitis B virus], HCV [hepatitis C virus] or HIV infection
- Has any other active infection requiring systemic therapy.
- Patients with active tuberculosis
- Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-PD-L1, anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor (TNFR) family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
- A diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Patient has had a prior monoclonal antibody, which does significantly interfere with the immune system or which does have a systemic therapeutic effect on the tumor within 4 weeks prior to randomization.
- Patient has not recovered (i.e., ≤ Grade 1 or at baseline) from any toxicity due to agents administered more than 4 weeks earlier. [Subjects with ≤ Grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study.]
- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
- Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- Has known hypersensitivity to methotrexate or pembrolizumab or any constituent of the products..
- Other active malignancy requiring treatment
- Lactating or pregnant women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (allowed methods of contraception, meaning methods with a rate of failure of less than 1% per year are combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally). Women of childbearing potential must have a negative pregnancy test (serum β-hCG) at Screening.
- Any psychiatric illness that would affect the patient's ability to understand the demands of the clinical trial
- Patient has already been recruited in this trial (does not include screening failures)
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm A
Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
|
Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
|
ACTIVE_COMPARATOR: Arm B
Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
|
Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor activity of pembrolizumab in SCCHN
Time Frame: 1 year
|
Overall survival (OS) rate
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life QLQC30 [EORTC QLQ-C30]
Time Frame: through study completion, an average of 6 years
|
QLQC30
|
through study completion, an average of 6 years
|
Quality of life HN35 [EORTCQLQ-H&N35]
Time Frame: through study completion, an average of 6 years
|
HN35
|
through study completion, an average of 6 years
|
Predictive biomarkers
Time Frame: through study completion, an average of 6 years
|
molecular-genetic pro-inflammatory markers
|
through study completion, an average of 6 years
|
Predictive biomarkers
Time Frame: through study completion, an average of 6 years
|
PD-L1 expression
|
through study completion, an average of 6 years
|
Time to failure of strategy (TTFS)
Time Frame: 1 year
|
defined as death, progressive disease (PD), treatment discontinuation ( or deterioration of Instrumental Activities of Daily Living (IADL score) by 2 points.
|
1 year
|
Efficacy of pembrolizumab in SCCHN
Time Frame: through study completion, an average of 6 years
|
Objective response rate (ORR) according to RECIST 1.1
|
through study completion, an average of 6 years
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: through study completion, an average of 6 years
|
Adverse event rates due to treatment with MTX and pembrolizumab in SCCHN measured according to CTCAE 4.03
|
through study completion, an average of 6 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QoL response QLQC30
Time Frame: through study completion, an average of 6 years
|
improvement in QLQC30
|
through study completion, an average of 6 years
|
QoL response HN35
Time Frame: through study completion, an average of 6 years
|
improvement in HN35
|
through study completion, an average of 6 years
|
prognostic value of tumor shrinkage
Time Frame: through study completion, an average of 6 years
|
objective response rate (ORR) according to RECIST 1.1
|
through study completion, an average of 6 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 2, 2018
Primary Completion (ACTUAL)
November 24, 2021
Study Completion (ACTUAL)
March 23, 2022
Study Registration Dates
First Submitted
May 31, 2017
First Submitted That Met QC Criteria
June 19, 2017
First Posted (ACTUAL)
June 21, 2017
Study Record Updates
Last Update Posted (ACTUAL)
February 6, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Head and Neck Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Pembrolizumab
- Methotrexate
Other Study ID Numbers
- AIO-KHT-0115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of Head and Neck
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Bristol-Myers SquibbOno Pharma USA IncCompletedCancer of Head and Neck | Cancer of the Head | Cancer of the NeckJapan
-
AstraZenecaCompletedCancer of Head and NeckSpain
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
University of Alabama at BirminghamAventis PharmaceuticalsCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neck NeoplasmsUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineTerminatedHead and Neck Cancer | Cancer of the Head and NeckUnited States
-
Royal Marsden NHS Foundation TrustRecruitingHead and Neck CancerUnited Kingdom
-
University of ChicagoCompletedHead and Neck CancerUnited States
Clinical Trials on Pembrolizumab Injection
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingESCC | Adjuvant Treatment | Lymph Node Positive | PembrolizumabChina
-
CHA UniversityMerck Sharp & Dohme LLCNot yet recruitingGestational Trophoblastic NeoplasiaKorea, Republic of
-
Hunan Province Tumor HospitalCompletedUncommon Pathological Types of Lung CancerChina
-
Hefei TG ImmunoPharma Co., Ltd.RecruitingMelanoma | Colorectal Cancer | Ovarian Cancer | Triple Negative Breast CancerUnited States
-
Summit TherapeuticsRecruitingNon-Small Cell Lung CancerUnited States, Canada
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Medical Center GroningenCompleted
-
Martin-Luther-Universität Halle-WittenbergUltimovacs ASA; Apotheke der Universitätsmedizin der Johannes Gutenberg-Universität... and other collaboratorsRecruitingHead and Neck Squamous Cell CarcinomaGermany